Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2024-06-26 Regulatory Filings
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for dealing in securities of the company. It references compliance with SEBI (Prohibition of Insider Trading) Regulations and the company's internal code of conduct. The purpose is to notify the market and regulatory bodies about the trading restrictions around the announcement of quarterly financial results. There is no financial data, report content, or detailed analysis present. The document is an announcement related to insider trading compliance and trading restrictions, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-06-26 English
Updates
Regulatory Filings Classification · 90% confidence The document text is extremely short (75 characters) and contains only a name, date, and a timestamp without any substantive content or context. There is no indication of any report, announcement, or financial data. Given the lack of information, this document does not fit any specific filing category and defaults to the fallback category for miscellaneous filings.
2024-06-21 English
Reply to Clarification- Financial results
Regulatory Filings
2024-06-07 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the publication of financial results for the quarter and year ended March 31, 2024. It references Regulation 30 and 47 of SEBI (LODR) Regulations, 2015, which pertain to disclosure requirements. The letter states that copies of the newspaper publication of the audited financial results have been enclosed and are also available on the company's website. The document length is short (2129 characters) and primarily serves as a notification of the publication of financial results rather than containing the financial results themselves. Therefore, this document is an announcement about the report's publication rather than the report itself. According to the "Menu vs Meal" rule, such documents should be classified as Report Publication Announcement (RPA).
2024-05-16 English
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document is a statement submitted to stock exchanges (BSE and NSE) regarding the utilization of IPO proceeds for the quarter ended March 31, 2024. It references Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of deviations or variations in the use of funds raised through public issues. The document explicitly states there is no deviation or variation in the use of funds. It includes a detailed table of fund utilization and confirms no comments from auditors or audit committee. The document length is 3981 characters, which is relatively short and primarily serves as a compliance statement rather than a full financial report. This fits the category of a Capital/Financing Update (CAP) as it updates on the use of capital raised through IPO and compliance with regulatory requirements on fund utilization. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a report publication announcement or regulatory filing in the fallback sense. Therefore, the best classification is Capital/Financing Update (CAP).
2024-05-14 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report' for the quarter ended March 31, 2024, related to the IPO proceeds utilization of Valiant Laboratories Limited. It is issued pursuant to SEBI regulations and includes detailed financial and compliance information about the use of IPO funds, verified by a Chartered Accountant. The report is comprehensive, covering issuer details, issue details, utilization of proceeds, and deployment of unutilized funds. It is not a brief announcement or a certification letter but a substantive report on the monitoring of IPO proceeds. This fits the category of a Capital/Financing Update (CAP), as it provides updates on the utilization of capital raised through the IPO and compliance with related regulations.
2024-05-14 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.